Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

254.17 +7.45 (+3.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,558,247
Open 245.85
Bid (Size) 253.21 (1)
Ask (Size) 255.53 (1)
Prev. Close 246.72
Today's Range 244.61 - 254.71
52wk Range 176.36 - 292.75
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97. 
Via Investor's Business Daily

Performance

YTD
+14.22%
+14.22%
1 Month
-10.18%
-10.18%
3 Month
+9.92%
+9.92%
6 Month
+36.02%
+36.02%
1 Year
+17.48%
+17.48%

More News

Read More
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
Vertex Narrowly Beats Quarterly Sales Forecasts, But Profit Misses By A Nickel
Via Investor's Business Daily
Vertex Reports First Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold
Via Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Via Investor's Business Daily
Earnings Scheduled For May 5, 2022
Via Benzinga
Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Analyzing Vertex Pharmaceuticals's Short Interest
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Via Benzinga
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much
Via Benzinga
Why Vertex Pharmaceuticals Shares Are Falling
Via Benzinga
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Vertex to Announce First Quarter 2022 Financial Results on May 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today
Via Benzinga
Best Healthcare Stocks To Buy In 2022
Via Talk Markets
Twitter And 4 Other Stocks Insiders Are Selling
Via Benzinga
4 Top Stock Trades for Monday: WMT, BAC, VRTX, COP
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.